Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for periodontitis in rheumatoid arthritis
NL-OMON25212Not yet recruiting
- Sponsor
- Sanofi
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of sarilumab in rheumatoid arthritis (RA) and periodontitis, sponsored by Sanofi. Primary endpoints: overall safety, periodontal safety and 1 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)periodontitis
Beyond the preview
Go deeper on NL-OMON25212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25212.